title: High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor.
abstract: The nuclear protein high mobility group box protein 1 (HMGB1) promotes inflammation upon extracellular release. HMGB1 induces proinflammatory cytokine production in macrophages via Toll-like receptor (TLR)-4 signaling in a redox-dependent fashion. Independent of its redox state and endogenous cytokine-inducing ability, HMGB1 can form highly immunostimulatory complexes by interaction with certain proinflammatory mediators. Such complexes have the ability to enhance the induced immune response up to 100-fold, compared with induction by the ligand alone. To clarify the mechanisms for these strong synergistic effects, we studied receptor requirements. Interleukin (IL)-6 production was assessed in supernatants from cultured peritoneal macrophages from mice each deficient in one of the HMGB1 receptors (receptor for advanced glycation end products [RAGE], TLR2 or TLR4) or from wild-type controls. The cultures were stimulated with the TLR4 ligand lipopolysaccaride (LPS), the TLR2 ligand Pam₃CysSerLys₄ (Pam₃CSK₄), noninflammatory HMGB1 or each TLR ligand in complex with noninflammatory HMGB1. The activity of the HMGB1-TLR ligand complexes relied on engagement of the same receptor as for the noncomplexed TLR ligand, since HMGB1-LPS complexes used TLR4 and HMGB1-Pam₃CSK₄ complexes used TLR2. Deletion of any of the intracellular adaptor molecules used by TLR2 (myeloid differentiation factor-88 [MyD88], TIR domain-containing adaptor protein [TIRAP]) or TLR4 (MyD88, TIRAP, TIR domain-containing adaptor-inducing interferon-β [TRIF], TRIF-related adaptor molecule [TRAM]) had similar effects on HMGB1 complex activation compared with noncomplexed LPS or Pam₃CSK₄. This result implies that the enhancing effects of HMGB1-partner molecule complexes are not regulated by the induction of additional signaling cascades. Elucidating HMGB1 receptor usage in processes where HMGB1 acts alone or in complex with other molecules is essential for the understanding of basic HMGB1 biology and for designing HMGB1-targeted therapies.
authors.affiliation: Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden. hulda.hreggvidsdottir@ki.se
authors.forename: Hulda Sigridur
authors.initials: HS
authors.lastname: Hreggvidsdóttir
authors.forename: Anna M
authors.initials: AM
authors.lastname: Lundberg
authors.forename: Ann-Charlotte
authors.initials: AC
authors.lastname: Aveberger
authors.forename: Lena
authors.initials: L
authors.lastname: Klevenvall
authors.forename: Ulf
authors.initials: U
authors.lastname: Andersson
authors.forename: Helena Erlandsson
authors.initials: HE
authors.lastname: Harris
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism*; D024243:HMGB1 Protein / Q000235:genetics / Q000378:metabolism*; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism; D008070:Lipopolysaccharides / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics / Q000378:metabolism; D051381:Rats; D051195:Toll-Like Receptor 2 / Q000235:genetics / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000235:genetics / Q000378:metabolism
chemical_list: D016207:Cytokines; D024243:HMGB1 Protein; D015850:Interleukin-6; D008070:Lipopolysaccharides; D053594:Myeloid Differentiation Factor 88; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4
references.citation: Blood. 2007 Sep 15;110(6):1970-81
references.pmid: 17548579
references.citation: J Exp Med. 2000 Aug 21;192(4):565-70
references.pmid: 10952726
references.citation: Blood. 2005 Jul 15;106(2):609-16
references.pmid: 15802534
references.citation: Nat Immunol. 2010 May;11(5):373-84
references.pmid: 20404851
references.citation: J Immunol. 2009 Nov 15;183(10):6244-50
references.pmid: 19890065
references.citation: Nature. 2002 Jul 11;418(6894):191-5
references.pmid: 12110890
references.citation: Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11542-7
references.pmid: 21709231
references.citation: J Exp Med. 2008 Dec 22;205(13):3007-18
references.pmid: 19064698
references.citation: Arthritis Res Ther. 2011 Aug 26;13(4):R136
references.pmid: 21871094
references.citation: J Immunol. 2005 Jun 15;174(12):7506-15
references.pmid: 15944249
references.citation: Annu Rev Immunol. 2011;29:139-62
references.pmid: 21219181
references.citation: J Cell Biol. 2001 Mar 19;152(6):1197-206
references.pmid: 11257120
references.citation: Antioxid Redox Signal. 2011 Apr 1;14(7):1315-35
references.pmid: 20969478
references.citation: Science. 1999 Jul 9;285(5425):248-51
references.pmid: 10398600
references.citation: J Leukoc Biol. 2009 Sep;86(3):655-62
references.pmid: 19564572
references.citation: J Leukoc Biol. 2007 Jan;81(1):49-58
references.pmid: 16980512
references.citation: Immunity. 2008 Jul 18;29(1):21-32
references.pmid: 18631454
references.citation: Eur J Immunol. 2011 Sep;41(9):2753-62
references.pmid: 21660935
references.citation: Mol Med. 2006 Apr-Jun;12(4-6):105-14
references.pmid: 16953558
references.citation: Shock. 2006 Jun;25(6):571-4
references.pmid: 16721263
references.citation: J Immunol. 2009 Sep 15;183(6):3642-51
references.pmid: 19717524
references.citation: Nat Immunol. 2007 May;8(5):487-96
references.pmid: 17417641
references.citation: Crit Care Med. 2007 Dec;35(12):2799-804
references.pmid: 17901841
references.citation: Nature. 2009 Nov 5;462(7269):99-103
references.pmid: 19890330
references.citation: J Immunol. 2008 Feb 15;180(4):2531-7
references.pmid: 18250463
references.citation: Am J Physiol Cell Physiol. 2006 Mar;290(3):C917-24
references.pmid: 16267105
references.citation: J Immunol. 2008 Apr 1;180(7):5067-74
references.pmid: 18354232
references.citation: Mol Med. 2010 Nov-Dec;16(11-12):479-90
references.pmid: 20811657
references.citation: J Leukoc Biol. 2009 Sep;86(3):609-15
references.pmid: 19414537
references.citation: Scand J Immunol. 2005 Jan;61(1):1-9
references.pmid: 15644117
references.citation: Xenotransplantation. 2007 Nov;14(6):636-41
references.pmid: 17991152
references.citation: Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11942-7
references.pmid: 20547845